Sumitomo Dainippon Pharma Co., Ltd. announced division realignment, effective April 1, 2018. Regenerative & Cellular Medicine Manufacturing Plant is established. To coincide with the commencement of operations of an iPS-cell-derived cellular medicine manufacturing facility within Central Research Laboratories (Suita, Osaka) in March of 2018, Regenerative & Cellular Medicine Manufacturing Plant is established to supervise the facility. The organizations related to the business of regenerative and cellular medicine (Regenerative & Cellular Medicine Office, Regenerative & Cellular Medicine Kobe Center, Regenerative & Cellular Medicine Manufacturing Plant) promote early commercialization of the business through close coordination. Furthermore, Japan Business Unit is established as a virtual organization, effective April 1, 2018. The company aims to increase the business profitability in Japan through integrated operation of the Japan business by devising strategic units and investment units designed specifically for it. Japan Business Unit is comprised of the following organizations and consolidated subsidiaries.
The company appointed Kazuhiro Takada, currently with Sumitomo Pharmaceuticals (Suzhou) Co., Ltd., as new Executive Officer, effective April 1, 2018. Hajime Kinuta, currently Executive Officer, Senior Director, Corporate Governance; Corporate Service Center is retiring Executive Officer, effective March 31, 2018.
Sumitomo Pharma Co., Ltd. (formerly Sumitomo Dainippon Pharma Co., Ltd.) specializes in development, manufacturing and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- pharmaceuticals (92.9%): for cardiovascular, gastrointestinal and infectious diseases, central nervous systems disorders and allergies treatment;
- other (7.1%): veterinary drugs, food additives, industrial chemical products, etc.
Net sales are distributed geographically as follows: Japan (39.8%), the United States (50.4%), North America (0.9%) and other (8.9%).